TScan Therapeutics(TCRX) - 2023 Q1 - Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to________________________ Commission File Number: 001-40603 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 82-5282075 (State or other jurisdiction of incorporation or organization) 830 Winter Street, Walt ...